相关实验视频

Updated: Jun 12, 2025

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

一种针对Mycobacterium结核病细胞壁生物合成的阿里硫胺

Renee Allen¹, Lauren Ames¹, Vanessa Pietrowski Baldin¹

¹Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.

Antimicrobial agents and chemotherapy

|September 26, 2024

概括

这项研究揭示了一种新的阿里硫胺候选药物,其向Mycobacterium结核病细胞壁合成. 细菌分析和耐药性研究强烈表明MmpL3是可能的分子标.

科学领域:

微生物学微生物学
药用化学医学化学
药物发现药物发现药物发现

背景情况:

结核病仍然是一个重大的全球健康威胁,需要新的治疗策略.
了解新的抗结核剂的作用机制对于药物开发至关重要.
阿里硫胺是有前途的化合物类别,具有针对Mycobacterium tuberculosis的潜在活性.

研究的目的:

调查一种新合成的阿里苏尔胺的作用机制,其对抗Mycobacterium tuberculosis的全细胞活性已被证明.
为了确定特定的分子标和受该化合物影响的途径.

主要方法:

二胺化合物的化学合成和表征.
在体外对细胞外和细胞内Mycobacterium结核病细菌进行检测.
使用HepG2细胞进行细胞毒性评估以确定选择性.
细菌细胞学分析以阐明作用机制.
基因表达分析 (IniB促进体) 和代谢分析 (ATP生产).
涉及MmpL3突变的耐药性研究.

主要成果:

合成的硫胺对细胞外和细胞内Mycobacterium tuberculosis表现出强烈的活性.
该化合物表现出选择性,对HepG2细胞的活性最小.
细菌细胞学分析表明细胞壁合成中断,类似于MmpL3抑制剂.
该药物诱导了IniB促进体表达和增加了ATP的产生,而没有诱导活性氧物种.
在MmpL3 (S591I) 中的一种特定突变赋予了对该化合物的低水平耐药性.

结论:

烯硫胺化合物有效地准了Mycobacterium tuberculosis中的细胞壁生物合成.
酸出口商MmpL3被确定为这种新型候选药物的最可能的分子标.
这些发现支持进一步开发这种用于结核病治疗的阿里硫胺.

关键词:

MmpL3MmpL3MMPL3MMPL3MMPL3MMPL3MMPL3MMPL3MMPL3MMPL3MMPL3MMPL3MMPL3MMPL3MMPL3MMPL3MMPL3MMPL3MMPL3MMPL3MMPL3MMPL3 这是抗结核的抗结核药物.细胞壁上的细胞壁.作用的作用方式.菌根细菌 (mycobacteria) 是一种细菌.结核病是一种肺结核病.

更多相关视频

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth

Published on: January 7, 2022

相关概念视频

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Defense Against Bacterial Pathogens

Defense Against Bacterial Pathogens

The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...